CoChat

Therapeutic pipeline in nonalcoholic steatohepatitis

Vuppalanchi, Raj, Noureddin, Mazen, Alkhouri, Naim, Sanyal, Arun J. · 2021 · Nature Reviews Gastroenterology & Hepatology

The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.

Abstract

Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance rapidly. Accordingly, the field has moved from describing the clinical phenotype through the presence of nonalcoholic steatohepatitis (NASH) and degree of fibrosis to deep phenotyping with a description of associated comorbidities, genetic polymorphisms and environmental influences that could be associated with disease progression. These insights have fuelled a robust therapeutic pipeline across a variety of new targets to resolve steatohepatitis or reverse fibrosis, or both. Additionally, some of these therapies have beneficial effects that extend beyond the liver, such as effects on glycaemic control, lipid profile and weight loss. In addition, emerging therapies for NASH cirrhosis would have to demonstrate either reversal of fibrosis with associated reduction in portal hypertension or at least delay the progression with eventual decrease in liver-related outcomes. For non-cirrhotic NASH, it is the expectation that reversal of fibrosis by one stage or resolution of NASH with no worsening in fibrosis will need to be accompanied by overall survival benefits. In this Review, we summarize NASH therapies that have progressed to phase II and beyond. We also discuss some of the potential clinical challenges with the use of these new therapies when approved.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41575-020-00408-y

Cites

191 of 191 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 191 references

Research works printed but not linked: 12

  1. Siemens Healthineers. FDA grants breakthrough device designation to Siemens Healthineers Enhanced Liver Fibrosis (ELF™) Test. Siemens https://www.siemens-healthineers.com/en-us/press-room/press-releases/elftest.html (2018).
  2. Ratziu, V. et al. One-year results of the global phase 2b randomized placebo-controlled ARREST trial of aramchol, a stearoyl CoA desaturase inhibitor, in patients with NASH [abstract]. Hepatology 68, LB-5 (2018).
  3. Frenette, C. T. et al. Emricasan (IDN-6556) orally for 6 months in patients with cirrhosis and elevated MELD score improves liver function [abstract]. Hepatology 64, 1042A (2016).
  4. Lucas, K. J. et al. Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from part C of the phase 2 FLIGHT-FXR study [abstract 139]. Hepatology 72, 101A–102A (2020).
  5. ENANTA Pharmaceuticals. ENANTA announces positive results of ARGON-1 study of its lead FXR agonist, EDP-305, for the treatment of NASH. ENANTA Pharmaceuticals https://www.enanta.com/investors/news-releases/press-release/2019/Enanta-Announces-Positive-Results-of-ARGON-1-Study-of-its-lead-FXR-Agonist-EDP-305-for-the-Treatment-of-NASH/default.aspx (2019).
  6. Lawitz E, B. M. et al. MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with nonalcoholic steatohepatitis: a 12-week, randomized, placebocontrolled study [abstract LB16]. J. Hepatol. 73, S132 (2020).
  7. Amin, N. et al. PF-05221304 (PF’1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCI), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and alt - phase 2a, dose-ranging study [abstract]. Hepatology 70, 21A–22A (2019).
  8. Harrison, S. A. et al. Efruxifermin (EFX), a long-acting Fc-FGF21 fusion protein, administered for 16 weeks to patients with NASH substantially reduces liver fat and ALT, and improves liver histology: analysis of a randomized, placebo-controlled, phase 2a study (balanced) [abstract]. Hepatology 72, 6A–7A (2020).
  9. Gilead. Gilead announces topline results from phase 2 ATLAS study in patients with bridging fibrosis (F3) and compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH). Gilead https://www.gilead.com/news-and-press/press-room/press-releases/2019/12/gilead-announces-topline-results-from-phase-2-atlas-study-in-patients-with-bridging-fibrosis-f3-and-compensated-cirrhosis-f4-due-to-nonalcoholic-s (2019).
  10. CymaBay Therapeutics. CymaBay therapeutics halts clinical development of seladelpar. CymaBay Therapeutics https://ir.cymabay.com/press-releases/detail/476/cymabay-therapeutics-halts-clinical-development-of-seladelpar (2019).
  11. CymaBay Therapeutics. FDA lifts all clinical holds on seladelpar. CymaBay Therapeutics https://ir.cymabay.com/press-releases/detail/485/fda-lifts-all-clinical-holds-on-seladelpar (2020).
  12. Younossi, Z. M. et al. The impact of pruritus on patient-reported outcomes (Pros) in patients with non-alcoholic steatohepatitis (NASH) treated with obeticholic acid (OCA) [abstract]. Hepatology 70, 39A–40A (2019).

Cited by

See all 292

Metadata

Authors
Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J.
Affiliations
  • Indiana University School of Medicine (US)
  • Cedars-Sinai Medical Center (US)
  • Arizona Liver Health (US)
  • Virginia Commonwealth University (US)
Corresponding author
Sanyal, Arun J.
Venue
Nature Reviews Gastroenterology & Hepatology
Published
2021-02-10
Volume
18
Issue
6
Pages
373-392
ISSN
  • 1759-5045 (ISSN-L)
  • 1759-5053
OpenAlex
W3126379854
Cited by
278
References
191
Citations by year
2026: 17 · 2025: 31 · 2024: 58 · 2023: 61 · 2022: 80 · 2021: 31
FWCI
8.88
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Gastroenterology & Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, fibrosis reversal, NASH cirrhosis, drug development, disease pathophysiology, comorbidities, genetic polymorphism, portal hypertension, liver-related outcomes
MeSH terms
Drug Development, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Liver Cirrhosis, Disease Progression, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic pipeline in nonalcoholic steatohepatitis. https://app.cochat.ai/papers/10.1038/s41575-020-00408-y
The paper
Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021). Therapeutic pipeline in nonalcoholic steatohepatitis. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-020-00408-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.